TABLE 4.
Pathology and clinical characteristics of patients who went on to develop metastatic recurrence
| Age (y) | Gender | Esophageal cancer type | R0 | High-risk pathologic features | Depth of submucosal invasion (μm) | Adjuvant therapy | Type of recurrence | Time to recurrence (mo) |
|---|---|---|---|---|---|---|---|---|
| 74 | Female | EAC | No | VM+, LVI+, poorly differentiated+ | N/A | Radiation therapy | Distant metastases (brain, liver) | 17 |
|
| ||||||||
| 66 | Male | EAC | No | VM+, LVI−, poorly differentiated+ | 1200 | Chemotherapy | Distant metastases (liver, peritoneal) | 13 |
|
| ||||||||
| 57 | Male | EAC | No | VM+, LVI−, moderately differentiated− | 2000 | CRT | Lymph nodes | 4 |
|
| ||||||||
| 81 | Male | EAC | No | VM+, LVI−, moderately differentiated− | N/A | CRT | Lymph nodes | 14 |
|
| ||||||||
| 82 | Male | EAC | No | VM+, LVI−, moderately differentiated− | 2000 | Surgery (liver metastases found at time of surgery) | Distant metastases (liver) | 2 |
LVI, Lymphovascular invasion; EAC, esophageal adenocarcinoma; CRT, chemoradiation therapy; VM, vertical margin; N/A, not applicable.